IBA Launches Quasar® Grid3D Advantage
- LOUVAIN-LA-NEUVE,Belgium (May 3,2025) – Ion Beam Applications SA (IBA),a global leader in particle acceleration technology and a major provider of dosimetry and quality assurance (QA) solutions,today announced the...
- The advanced system is designed for facilities requiring precise magnetic resonance imaging (MRI) distortion analysis for stereotactic planning, ensuring the geometric accuracy of MRI images used in radiotherapy.
- MRI is increasingly vital in radiotherapy due to its superior soft tissue contrast without the use of ionizing radiation.
IBA Launches QUASAR® GRID3D Advantage for MRI-Guided Radiotherapy QA
Table of Contents
- IBA Launches QUASAR® GRID3D Advantage for MRI-Guided Radiotherapy QA
- IBA Launches QUASAR® GRID3D Advantage: Your Questions Answered
- What is QUASAR® GRID3D Advantage?
- Why is MRI distortion analysis important in radiotherapy?
- How does the GRID3D advantage system work?
- What are the key benefits of using GRID3D advantage?
- What did industry experts say about GRID3D Advantage?
- Where was the launch of QUASAR® GRID3D Advantage announced?
- Who is IBA (Ion Beam Applications SA)?
- Where can I find more information about IBA?
- Who can I contact for more information?
LOUVAIN-LA-NEUVE,Belgium (May 3,2025) – Ion Beam Applications SA (IBA),a global leader in particle acceleration technology and a major provider of dosimetry and quality assurance (QA) solutions,today announced the release of its new image distortion analysis system,QUASAR® GRID3D Advantage.The proclamation was made during the European Society for Radiotherapy and Oncology (ESTRO) 2025 Congress in vienna, Austria.
The advanced system is designed for facilities requiring precise magnetic resonance imaging (MRI) distortion analysis for stereotactic planning, ensuring the geometric accuracy of MRI images used in radiotherapy. It combines automated analysis via user-friendly software with a versatile solution that includes multiple adapters.
ensuring Precision in MRI-Guided Radiotherapy
MRI is increasingly vital in radiotherapy due to its superior soft tissue contrast without the use of ionizing radiation. In MRI-guided radiotherapy, accurate imaging is crucial for targeting tumors while protecting surrounding healthy tissue. Tho, geometric distortions in MRI images can compromise treatment precision. robust QA tools like GRID3D Advantage are essential for ensuring image fidelity and boosting clinical confidence.
Industry Outlook
Ian Paddick, director of Medical Physics Limited, stated, “For the first time, the reference method for measurement of the image distortion, the Known Target technique, is available for the Vantage Frame configuration. This represents a huge step forward in our ability to provide full quality assurance for gamma knife radiosurgery.“
Jean-Marc Bothy, president of IBA Dosimetry, commented, “We understand that MRI imaging has become an integral part of radiotherapy work, in particular in the case of small fields of treatment where millimeters can have an impact on the results of the treatment. Consequently, the quality insurance of geometric distortion is no longer optional but essential. Grid3D Advantage reflects our commitment to provide clinicians and researchers with specific tools to assess geometric distortion of 3D MRI.“
About IBA
IBA (Ion Beam Applications SA) is a global leader in particle accelerator technology. The company is a leading provider of equipment and services for proton therapy, considered the most advanced form of radiotherapy, as well as for industrial sterilization, radiopharmaceuticals, and dosimetry. Headquartered in Louvain-la-Neuve, Belgium, IBA employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp),committed to meeting high standards of social and environmental performance.
IBA is listed on the pan-European exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
for more details, visit: www.iba-worldwide.com
Contacts
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
ICR Healthcare
Amber Fennell, Angela Gray, Chris Welsh
+44 (0) 20 3709 5700
IBA@icrhealthcare.com
- 250503-PR-GRID-Advantage-FR
IBA Launches QUASAR® GRID3D Advantage: Your Questions Answered
What is QUASAR® GRID3D Advantage?
QUASAR® GRID3D Advantage is a new image distortion analysis system launched by IBA (Ion Beam Applications SA). It’s designed to help facilities ensure the geometric accuracy of MRI images used in radiotherapy. This system allows for precise magnetic resonance imaging (MRI) distortion analysis, crucial for stereotactic planning.
Why is MRI distortion analysis important in radiotherapy?
MRI is used in radiotherapy due to its superior soft tissue contrast without ionizing radiation. However, geometric distortions in MRI images can compromise treatment precision. Accurate imaging is paramount for targeting tumors while protecting surrounding healthy tissue. Robust Quality Assurance (QA) tools like GRID3D Advantage are essential to ensure image fidelity and boost clinical confidence.
How does the GRID3D advantage system work?
The system combines automated analysis via user-friendly software with a versatile solution that includes multiple adapters. This allows for detailed assessment and correction of MRI distortions.
What are the key benefits of using GRID3D advantage?
The primary benefit is ensuring the geometric accuracy of MRI images. This leads to more precise radiotherapy treatments, minimizing the impact on healthy tissue. the system also enhances overall clinical confidence in the treatment planning process.
What did industry experts say about GRID3D Advantage?
Ian Paddick, Director of Medical Physics Limited, stated, ”For the first time, the reference method for measurement of the image distortion, the Known Target technique, is available for the Vantage Frame configuration. This represents a huge step forward in our ability to provide full quality assurance for gamma knife radiosurgery.” Jean-Marc Bothy, president of IBA Dosimetry, added, “We understand that MRI imaging has become an integral part of radiotherapy work, in particular in the case of small fields of treatment where millimeters can have an impact on the results of the treatment. Consequently, the quality insurance of geometric distortion is no longer optional but essential. Grid3D Advantage reflects our commitment to provide clinicians and researchers with specific tools to assess geometric distortion of 3D MRI.”
Where was the launch of QUASAR® GRID3D Advantage announced?
The proclamation was made during the European Society for Radiotherapy and Oncology (ESTRO) 2025 Congress in Vienna, Austria. ESTRO is a leading event for professionals in radiation oncology.
Who is IBA (Ion Beam Applications SA)?
IBA (Ion Beam Applications SA) is a global leader in particle accelerator technology. The company is a leading provider of equipment and services for proton therapy, considered the most advanced form of radiotherapy. IBA also provides solutions for industrial sterilization, radiopharmaceuticals, and dosimetry. They are headquartered in Louvain-la-Neuve, Belgium, and employ approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) committed to meeting high standards of social and environmental performance.
Where can I find more information about IBA?
You can visit the IBA website at www.iba-worldwide.com for more details.
Who can I contact for more information?
For corporate communications, contact:
Olivier Lechien
Corporate Communication Director
+32 10 475 890
For inquiries thru ICR Healthcare, contact:
ICR Healthcare
Amber Fennell, Angela Gray, Chris Welsh
+44 (0) 20 3709 5700
- 250503-PR-GRID-Advantage-FR